Valencia, 7 June. (European Press) –
Jules Hoffmann, the 2011 Nobel Prize in Physiology or Medicine, considered that it should “in theory” be “no problem” to receive a second dose of the coronavirus vaccine from a different pharmaceutical company than the first.
This is how the biologist announced himself at the press conference for the Jaume I Awards, where this year he is participating as a jury. Hoffman was honored in 2011 for his contributions to immunology and vaccines alongside Bruce Butler and Ralph M. Steinman.
Hoffman stated that he was not aware of this controversy, as the trend in France is for the second vaccine to be of the same type as the first. However, he does not see why “changing the types of vaccines could be harmful”.
The biologist also noted that we are not “at the end of efforts with Covid-19”. “We are enjoying the benefits of the work done on messenger antibodies, but many other aspects of the virus have yet to be attacked,” he explained.
In this sense, he hoped that in two or three years it would be possible to develop molecules that could prevent the spread of the virus, as happened with HIV. She also warned of a lack of knowledge regarding infectious diseases.
Yes, he was optimistic about learning from the pandemic: “For the next pandemic, which is to come, all the efforts that have gone into will help us be better prepared,” he said, highlighting the progress made in the last 15 months.